New Horizons in Ovarian Cancer: Expert Insights into the Role of Genetic Biomarkers in Precision Therapy

October 8, 2021

Attendees of these regional meetings will gain an appreciation of the genes involved in the DNA damage response pathways and their role in tumorigenesis, the latest guidelines on genetic testing/counseling for mutations in this pathway, and the clinical implications of testing results (such as the use of PARP inhibitor for treatment). There will also be extensive discussion about the evolving role of the OB/GYN practitioner in genetic testing/counseling and management of ovarian cancer survivors on PARP inhibitor therapy.


Presented by Creative Educational Concepts, Inc.

Supported through independent educational grants from AstraZeneca and Merck.

This is an independent CME Satellite Event and is not part of the official ACOG District IV 2021 Annual District Meeting.

Target Audience

This activity is targeted to gynecologists, obstetricians, and other related healthcare professionals attending the 2021 American College of Obstetricians and Gynecologists (ACOG) Clinical District Meetings.

Learning Objectives

  • Review the DNA damage response (DDR) pathway and its role in tumorigenesis of ovarian cancers and outline the various mutations that cause defects in this pathway. 
  • Review the latest clinical recommendations on genetic testing and counseling in ovarian cancer and discuss the therapeutic implications of identifying mutations in the DDR, as well as other relevant markers of genomic instability (e.g., HRD). 
  • Discuss current and emerging clinical data regarding the safety and efficacy of PARP inhibitors in ovarian cancer patients.   
  • Assess the evolving role of OB/GYN practitioners for genetic testing/counseling in patients who are at risk for or have deficiencies in the HRR pathway and discuss multidisciplinary strategies to ensure the appropriate management of patients on PARP inhibitors.    
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Course opens: 
09/13/2021
Course expires: 
11/08/2021
Event starts: 
10/08/2021 - 12:00pm
Event ends: 
10/08/2021 - 1:00pm
Rating: 
0

5 min Welcome and Introductions/Pre-test 

15 min The DNA Damage Response Pathway: BRCA and Beyond 

15 min PARP Inhibitors in Ovarian Cancer Treatment: A Possible Achilles Heel? 

20 min Improving Patient Outcomes in Ovarian Cancer: Practical Strategies for the OB/GYN Practice 

5 min Conversations with the Experts/Audience Q&A/Post-test 

Live Virtual Event
ACOG District IV
12:00PM ET
United States

Robert M. Wenham, MD, MS, FACOG, FACS
Chair, Department of Gynecologic Oncology
Moffitt Cancer Center
Tampa, Florida

 

 

Dr. Robert Wenham is a gynecologic oncologist and Chair of the Gynecologic Oncology Program at Moffitt Cancer Center, a Senior Member of the Chemical Biology and Molecular Therapeutics Program, and Professor of Oncologic Sciences in the Morsani School of Medicine.  He has received the Molly Cade Ovarian Cancer Research Award from the Gynecologic Cancer Foundation and been awarded a HOW Fellowship for work in ovarian cancer.  He is principal investigator for numerous clinical trials to improve cancer care for women with a focus on novel drugs, immunotherapy, and cellular therapy for the treatment of gynecologic cancers. He serves on advisory committees, steering committees, or data safety committees for clinical studies. He is also an expert in complex abdominopelvic surgeries including exenterative surgery. 


In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.

Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Planners:
Vanessa Carranza, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.

Robert M. Wenham, MD, MS, FACOG, FACS–has disclosed that he is a consultant for GSK/Tesaro, Merck, Ovation Diagnostics, Regeneron, Seagen, Sonnet Biotherapeutics, and Shattuck Labs. He receives grant/research support from Merck. He is a major stock shareholder in Ovation Diagnostics and is on the speakers’ bureau for ONC Live and Curio Science.

Authors/Presenters:
Ursula Matulonis, MD–has disclosed that she is a consultant for AstraZeneca, Merck, NextCure, and Novartis. He receives financial or material support from DSMB and Symphogen. 

Angeles Alvarez Secord, MD– has disclosed that she receives grant/research supports from AbbVie, AstraZeneca, Clovis, Merck, and Oncoquest. 

Robert M. Wenham, MD, MS, FACOG, FACS–has disclosed that he is a consultant for GSK/Tesaro, Merck, Ovation Diagnostics, Regeneron, Seagen, Sonnet Biotherapeutics, and Shattuck Labs. He receives grant/research support from Merck. He is a major stock shareholder in Ovation Diagnostics and is on the speakers’ bureau for ONC Live and Curio Science.

Shannon N. Westin, MD, MPH–has disclosed that she is a consultant for AstraZeneca, Clovis Oncology, GSK/Tesaro, and Novartis. She receives grant/research support from AstraZeneca, Clovis Oncology, GSK/Tesaro, and Novartis.

Content Reviewer: 
Justine Cooper Pickarski - has no relevant financial relationships to disclose in relation to the content of this activity.

 

 

In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Medicine (ACCME) 

CEC designates this live, virtual educational activity for a maximum of 1.0 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity. Upon completion of a CE request form, statements of credit for physicians will be issued. 

 

   

 

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Please login or register to take this course.